INTRODUCTION

Post-operative nausea and vomiting (PONV)
is a common distressing symptom occurring after a surgical procedure. The incidence of PONV varies from 20% to 30% and is higher (70% to 80%) in patients at high risk. [1, 2] It has a multifactorial etiology involving anesthetic, surgical, and individual risk factors. [3] Intraperitoneal surgeries like laparoscopy, ear nose and throat, neurosurgery, breast, strabismus, laparotomy, and plastic surgery are associated with a higher incidence of PONV. [4] Laparoscopic cholecystectomy is a commonly performed surgery and the incidence of PONV in these patients is reported to be 53% to 72%. [5, 6] Increased patient discomfort due to PONV remains a cause of concern for the surgeons as well as anesthesiologists and has some definite implications on the recovery. This often leads to a delay in the discharge of these patients with increased burden on hospital. Most of the times patients weigh the distress associated with PONV as more unpleasant than the post-operative pain itself. [7] 5HT 3 receptor antagonists, e.g., ondansetron, granisetron, and tropisetron, are by far the best-studied drugs and have been used extensively either alone or in combination with other antiemetics like metoclopramide, dexamethasone, droperidol. [8, 9] Ramosetron, a newly introduced 5HT 3 receptor antagonist, is said to be more selective and potent, [10] [11] [12] but there is a relative scarcity of randomized controlled trials or case-controlled studies on the use of ramosetron. Therefore, we designed a prospective, randomized, double-blind controlled study to compare the efficacy and safety of ramosetron and ondansetron in patients undergoing standard 4-port laparoscopic cholecystectomy.
Aims of the study 1. To study the efficacy and side effects of ondansetron in patients undergoing standard 4-port laparoscopic cholecystectomy (control group). 2. To study the efficacy and side effects of ramosetron in patients undergoing standard 4-port laparoscopic cholecystectomy (study group). 3. To compare the efficacy and side effects of ondansetron and ramosetron in patients undergoing standard 4-port laparoscopic cholecystectomy.
MATERIALS AND METHODS
Female patients aged between 30 and 50 years (ASA Grade I and II) undergoing elective standard 4-port laparoscopic cholecystectomy at J. N. Medical College Hospital, A.M.U., Aligarh, were included in the present prospective study in a period from January 2010 to March 2011. Approval from the Institutional Ethics Committee was obtained.
Patients were included in the study after well-informed written consent, including the information that they would be part of this on-going institutional research. Patients with a history of motion sickness, gastrointestinal disease, patients receiving antiemetics within 24 h before surgery, patients on chronic steroid therapy, and patients with diabetes mellitus or cardiovascular disease will be excluded from the study. [13] A computer generated randomization list was prepared and patients were divided into two groups-the control group receiving ondansetron and the study group receiving ramosetron. Based on the previous studies advocating use of the minimum recommended doses, ramosetron in a dose of 0.3 mg [10] [11] [12] and ondansetron in a dose of 4 mg [9, 14, 15] were administered for prevention of PONV in the present study. Medications were prepared by a blinded paramedic not involved in the study in identical 5-ml syringes and were administered according to the randomization list. Patients were administered Lorazepam (0.5 mg) orally on the night before surgery and advised nil per orally from midnight. A well-defined anesthesia regimen was used in all the patients that was induced with inj. propofol 2 mg/ kg and inj. fentanyl 1-2 µg/kg. Intubation was facilitated by using inj. vecuronium 0.1 mg/kg. A nasogastric tube was inserted after securing the endotracheal tube in place. Anesthesia was maintained with nitrous oxide (66%) and sevoflurane (1-2%) in oxygen. Intra-operative muscle relaxation was maintained with inj. vecuronium. At the end of the surgery, inj. diclofenac 75 mg I.M. was given before the reversal of neuromuscular blockade to preempt the post-operative pain. Muscle relaxation was reversed with inj. neostigmine (0.04 mg/ kg) a n d i n j . g l y c o p y r r o l a t e ( 0 .0 1 m g /k g ) . Nasogastric suction was done to remove any residual gastric contents. Ondansetron (4 mg) or ramosetron (0.3 mg) was administered intravenously before shifting of the patient from the OR (operation room) to the post-operative unit (POP). All port sites were infiltrated with inj. bupivacaine (0.25%). Additional post-operative analgesia was provided with inj. tramadol 2 mg/ kg I.M. as and when required.
Intraoperative monitoring included heart rate, non-invasive blood pressure, PETCO 2 , oxygen saturation, and ECG. In the postoperative period, patients were monitored for nausea, vomiting, pain, vital signs, and postanesthetic discharge score. Patients were closely monitored for 48 h and any complaint of nausea, retching, and vomiting or adverse drug effect was recorded by an independent observer (usually a Resident Officer) who was blinded to the study. Inj. metoclopramide (10 mg I.V.) was administered as an additional rescue antiemetic in patients with two or more than two episodes of vomiting and/or significant nausea at any time within 48 h of operation. Exact timing of the administration of the rescue antiemetic was recorded.
Nausea was defined as a subjectively unpleasant sensation associated with awareness of the urge to vomit whereas retching was defined as the labored spasmodic, rhythmic contraction of the abdominal muscles without expulsion of gastric contents, and vomiting was defined as the forceful expulsion of gastric contents from the mouth.
[13] Nausea was measured using an 11 point numerical visual analogue scale with 0 = no nausea and 10 = nausea as bad as can be. A score of > 5 was considered severe, 5 = moderate and < 5 = minimal. The moderate and severe nausea was considered as major nausea. During the period of monitoring, the vomiting/retching episodes of >2 were considered severe, 2 as moderate, and <2 as mild. Rescue antiemetic consisted of inj. metoclopramide 0.15 mg/kg I.V. and was given for more than two episodes of vomiting. Vomiting occurring up to 24 h after surgery was taken as early vomiting whereas delayed vomiting consisted of vomiting occurring during 24-48 h after surgery. A complete response was defined as the absence of PONV. Any adverse drug effect occurring during the study period was diligently sought and documented.
Statistical analysis
Assuming an alpha error (α) of 0.05 and a complete response with ondansetron to be 70%, an improvement of 20% was considered clinically significant. A minimum number of 65 patients in each group were calculated to achieve a power of 80%. A P-value of <0.05 was considered as significant. All the data were recorded on standardized case report forms and exported for analysis in SPSS, version 17 (SPSS Inc., USA). All the statistical tests were two tailed. All the values were expressed as mean ± S.D.
RESULTS
During a period of 15 months, 130 adult f e m a l e s u n d e r g o i n g s t a n d a r d 4 -p o r t l a p a r o s c o p i c c h o l e c y s t e c t o m y w e r e
studied-65 patients in each of the two groups studied. Means (±s.d.) of age, height, and weight of the 130 patients were 39.4±4.42 years (range 30-43), 53.3±2.01 cm (range 147-159), and 53.3±2.01 kg (range 50-60), respectively. The study included 17 postmenopausal females (9 in the ramosetron group and 8 in the ondansetron group) with a ratio of premenopausal and postmenopausal of 6.6:1. The control group (Ondansetron) and the study group (Ramosetron) were comparable (P>0.05) with respect to the patients' demographic data and the durations of anesthesia, CO 2 insufflation, and surgery [ Table 1 ].
In first 24 h after surgery, complete response (No PONV) was observed in 28 patients of the ondansetron group and in 32 patients of the ramosetron group, and there was no statistical difference (P>0.05) between the two groups [ Table 2 ]. Complete response (No PONV) in the second 24 h after surgery was observed in 30 patients of the ondansetron group and in 45 patients of the ramosetron group, and the difference in this time period was statistically significant (P<0.05) between the two groups [ Table 2 ].
During the first 24 h after surgery, PONV observed in the two groups (37 and 33 in ondansetron and ramosetron groups, respectively) was not statistically different (P>0.05) but PONV requiring rescue antiemetic during the same period was significantly higher (P<0.05) in the ondansetron group as compared to the ramosetron group [ Table 2 ]. During the second 24 h after surgery, incidence of PONV was found higher in the ondansetron group as compared to the ramosetron group, and the difference during this period in the 
DISCUSSION
Laparoscopic surgery is followed by significant degrees of PONV in more than half of the patients. The etiology is multifactorial with vomiting centre receiving afferents from cerebral cortex, the viscera, and chemoreceptor trigger zone (CTZ). [16] The central action of CO 2 , rapid peritoneal distension, and activation of neurogenic pathways by traction reflexes and splanchnic pressure are implicated in causation of PONV after laparoscopic surgery. [17] [18] [19] Pharmacological therapy consists of anticholinergics (e.g., scopolamine), butyrophenones (e.g., droperidol), benzamides (e.g., metoclopramide), and antiserotonins ( e . g . , O n d a n s e t r o n ) . N o n -t r a d i t i o n a l antiemetics, e.g., propofol, dexamethasone, tandospirone, and midazolam, have also been used in the prophylaxis of PONV. However, anti-emetics in the group of anticholinergics, antihistaminics, butyrophenones, and benzamides are associated with a significant incidence of undesirable side effects like sedation, hypotension, dry mouth, dysphoria, restlessness, and extrapyramidal symptoms. Antiserotonins (5HT 3 receptor antagonists) are one of the most effective treatment options available for control of PONV after surgery under general anesthesia including laparoscopic cholecystectomy.
[13] 5HT 3 receptor antagonists exert their effects on the CTZ and at the vagal afferents in the gastrointestinal tract. [20] In our study, the two groups (ondansetron and ramosetron) were clinically matched with respect to the patients' demographic data, type of surgery, anesthetics administered, and analgesics used post-operatively. We observed PONV following standard 4-port laparoscopic cholecystectomy in a significant percentage of patients in the ondansetron group (56.9%) as well as ramosetron group (50.8%) and this is in tune with the observations of other workers. [5, 6] During the first 24 h after surgery, the difference in the incidence of PONV between the ondansetron group and the ramosetron group was not significant (P>0.05) although significantly lesser number of patients in the ramosetron group required rescue antiemetic. This suggests that PONV when it occurs in the ramosetron group is of lesser degree as compared to PONV occurring in the ondansetron group in the first 24 h after surgery. This is in partial agreement with the observations of Ryu and colleagues [21] who also reported significantly lower incidence of PONV in the ramosetron group as compared to the ondansetron group, especially within first 2 h after lap chole. Patients who received rescue antiemetics were classified as treatment failures by Naguib and associates; [9] with this criterion, our findings would not be really in disagreement with that of Ryu and colleagues. [21] In the second 24-h period after surgery, PONV was noted in 53.8% and 30.8% of patients in the ondansetron group and the ramosetron group respectively and the difference between the two groups was statistically significant (P<0.05). Furthermore, not only the number of patients with PONV not requiring rescue antiemetic but also the number of patients with PONV requiring rescue antiemetic was significantly less (P<0.05) in the ramosetron group as compared to the ondansetron group. This indicates greater efficacy of ramosetron during the second 24-h period also in terms of lesser incidence as well as lesser degree of PONV when it occurs. Our results during the 24-48 h after surgery are in full agreement with those of Fujii and associates [12] but differ from those of Ryu and colleagues. [21] The persistent response of ramosetron lasting over the period of 48 h after surgery may be a reflection of its more prolonged elimination half life (5.8 h) as compared to that of ondansetron, i.e., 4.5 h [22, 23] but this does not fully explain its prolonged action.
We observed episodes of retching in a significant percentage of patients (16.2% and 12.3% in the first and second 24-h after surgery respectively) although retching has not been reported/highlighted by majority of the investigators. The difference between the two groups was not significant (P>0.05) in the first 24-h after surgery but was found significant (P<0.05) in the second 24-h after surgery with lesser incidence in the ramosetron group. It is also interesting to note that a few patients in our study developed only retching without nausea/vomiting (three in each group)-a fact not mentioned in other studies.
In our study, we also recorded a significant incidence of adverse drug effects (14.6%) which were mild and transitory in nature and the difference between Ramosetron and Ondansetron groups was not found significant statistically (P>0.05).
The precise mechanism of ramosetron in the prevention of PONV remains unclear but it may have the same mechanism as granisetron which is reported to act on sites containing 5-HT3 receptors with demonstrated antiemetic effects. [24] Although the use of nitrous oxide still remains controversial, [25] [26] [27] anesthesia in the present study was maintained with nitrous oxide due to hospital financial constraints, which may have contributed to the emetogenic potential. Omitting nitrous oxide and using a continuous infusion of a short-acting opioid might have been a better choice. A multimodal approach with combination of two or more antiemetics has been recommended for more effective control of PONV in patients with two or more risk factors. Addition of dexamethasone to the newer 5HT3 receptor antagonists has been reported more efficacious in patients undergoing laparoscopic cholecystectomy. [28] It needs to mention that our study has a small limitation due to the absence of a placebo group. Our Institutional Ethics Committee considered the inclusion of a placebo group as unethical because a definite percentage of the patients would be unnecessarily exposed to this distressing symptom in the post-operative period. Placebo-controlled trial has been labeled unethical by other investigators also if active drugs are available. [29] Our study therefore concludes that ramosetron is safe and has a more potent antiemetic effect as compare to ondansetron in patients undergoing standard 4-port laparoscopic cholecystectomy and confirms the observations of Fujii and associates. [11] 
